Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stelara And Firmagon Suffer Setbacks In Draft NICE Appraisals

This article was originally published in The Pink Sheet Daily

Executive Summary

Janssen has until Jan. 17 to argue the cost-effectiveness of Stelara in the additional indication, psoriatic arthritis, while Ferring faces a restricted indication recommendation for Firmagon.

You may also be interested in...

Stelara's Triumph At NICE May Highlight Improved Focus on Drug Value

A patient access scheme from Janssen has seen Stelara through the NICE process for active psoriatic arthritis, but this doesn't mean the cost watchdog is back to focusing cost.

Janssen's Stelara Rejection At NICE Puts Innovation In The Spotlight

Janssen's Stelara has been blocked from the NHS by NICE because, although innovative, it is not the step change that the British reimbursement watchdog wants.

Ferring Firmagon’s “Positive” NICE Recommendation Still Not That Good

Severely restricted indication will see the prostate cancer drug’s revenues effectively dry up in the U.K.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts